Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fremanezumab, Migraine and Sleep
NCT04693533Phase 4Terminated
- Sponsor
- Beth Israel Deaconess Medical Center
- Start
- Jul 2021
- Primary completion
- Apr 2024
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 4 trial of fremanezumab in migraine, sleep disorder, sponsored by Beth Israel Deaconess Medical Center. Started Jul 2021; status: terminated.
02
Drugs
fremanezumab
03
Conditions
migrainesleep disorder
Beyond the preview
Go deeper on NCT04693533.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04693533.